Ontario

我们是谁

  • 4 月 5, 2022
    A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers
  • 4 月 5, 2022
    BMS-986253与Nivolumab或Nivolumab加Ipilimumab联合治疗晚期癌症的研究
  • 4 月 5, 2022
    肿瘤诊断精准免疫肿瘤学和体细胞靶向合理性（TAPISTRY）平台研究
  • 4 月 5, 2022
    活体肝移植治疗无法切除的结直肠癌肝转移灶
  • 4 月 5, 2022
    Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors
  • 4 月 5, 2022
    BMS-986288单独或与Nivolumab联合治疗晚期实体瘤的免疫疗法研究
  • 4 月 5, 2022
    一项针对晚期实体瘤患者的BMS-986340单药及与Nivolumab联合用药研究
  • 4 月 5, 2022
    Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)
  • 4 月 5, 2022
    A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
  • 4 月 5, 2022
    Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer